Submitted by mark
Guest Post by Jon Fleetwood
Editor’s note: This article’s headline has been updated to clarify that the FDA inset for Merck’s ERVEBO Ebola vaccine states that the vaccine “sheds” in more than 31% of those vaccinated with the drug. The prior headline said that the vaccine “‘Sheds’ Onto/Infects Others 31% of the Time.” It is more precise to simply say that the vaccine “sheds” in 31% of the vaccinated. This means that the “transmission of vaccine virus is a theoretical possibility,” according to the FDA insert. The word “Ebola” was also removed before “Bat Lab” toward the end of the headline, because although the Daily Mail has confirmed documents indicating the lab “could” study Ebola, the fact that the lab will study bats is sufficient. The article body still reports the Daily Mail’s confirmation of documents indicating the lab “could” study Ebola. The main point of the story has not been affected: a “shedding” Ebola vaccine has been given to Denver Health workers 65 miles from a proposed Fort Collins bat research lab that “could” study Ebola. A body subheadline has also been changed to clarify that the mortality rate in Ebola patients increases when they are treated with the drug Remdesivir.
